Anton Dofferhoff to Humans
This is a "connection" page, showing publications Anton Dofferhoff has written about Humans.
Connection Strength
0.036
-
Reduced Vitamin K Status as a Potentially Modifiable Risk Factor of Severe Coronavirus Disease 2019. Clin Infect Dis. 2021 12 06; 73(11):e4039-e4046.
Score: 0.008
-
[Diagnostic algorithm for COVID-19 at the ER]. Ned Tijdschr Geneeskd. 2020 05 14; 164.
Score: 0.007
-
Prior use of therapeutic anticoagulation does not protect against COVID-19 related clinical outcomes in hospitalized patients: A propensity score-matched cohort study. Br J Clin Pharmacol. 2021 12; 87(12):4839-4847.
Score: 0.002
-
Dysregulated Innate and Adaptive Immune Responses Discriminate Disease Severity in COVID-19. J Infect Dis. 2021 04 23; 223(8):1322-1333.
Score: 0.002
-
Risk factors for in-hospital mortality in laboratory-confirmed COVID-19 patients in the Netherlands: A competing risk survival analysis. PLoS One. 2021; 16(3):e0249231.
Score: 0.002
-
COVID-19-associated pulmonary aspergillosis: a prospective single-center dual case series. Mycoses. 2021 Apr; 64(4):457-464.
Score: 0.002
-
Response to correspondence concerning: "Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients". Int J Infect Dis. 2021 02; 103:478-479.
Score: 0.002
-
Chest CT in the Emergency Department for Diagnosis of COVID-19 Pneumonia: Dutch Experience. Radiology. 2021 02; 298(2):E98-E106.
Score: 0.002
-
Few bacterial co-infections but frequent empiric antibiotic use in the early phase of hospitalized patients with COVID-19: results from a multicentre retrospective cohort study in The Netherlands. Infect Dis (Lond). 2021 02; 53(2):102-110.
Score: 0.002
-
Vitamin K metabolism as the potential missing link between lung damage and thromboembolism in Coronavirus disease 2019. Br J Nutr. 2021 07 28; 126(2):191-198.
Score: 0.002
-
Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients. Int J Infect Dis. 2020 Dec; 101:283-289.
Score: 0.002
-
Automated Assessment of COVID-19 Reporting and Data System and Chest CT Severity Scores in Patients Suspected of Having COVID-19 Using Artificial Intelligence. Radiology. 2021 01; 298(1):E18-E28.
Score: 0.002
-
Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial. Lancet Gastroenterol Hepatol. 2019 04; 4(4):269-277.
Score: 0.002
-
Ribavirin steady-state plasma level is a predictor of sustained virological response in hepatitis C-infected patients treated with direct-acting antivirals. Aliment Pharmacol Ther. 2017 11; 46(9):864-872.
Score: 0.001